Abstract Growing evidence highlights the critical involvement of the ubiquitin-proteasome system in cancer development. As an essential component of the 26 S proteasome, Proteasome 26 S Subunit ATPase 2 (PSMC2) has been implicated in various malignancies, but its role in...
本文仅供医疗卫生等专业人士参考审批号：HS-P-A505A-2605-01435免...
Longer time with low estimated glomerular filtration rate increases the likelihood of preemptive and living donor kidney transplants in youth, though disparities persist by race Youth who spent more time with an estimated glomerular filtration rate (eGFR) at or below...
Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACCDose dependent and manageable AE profile, no new safety...
Preliminary mPFS of 15.2 months; mDOR not reached Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases ORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACC Dose dependent and manageable AE profile,...
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced an upcoming presentation of...
Rhea-AI Summary Black Diamond Therapeutics (Nasdaq: BDTX) reported positive Phase 2 results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations. Key data include preliminary mPFS of 15.2 months, ORR of 60%, DCR of 91%, CNS ORR of 86%,...
This is a paid press release. Contact the press release distributor directly with any inquiries. Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations Black Diamond Therapeutics, Inc Thu, May 21,...
BH-30643 has demonstrated encouraging clinical activity against diverse EGFR genotypes and on-target resistance in heavily pretreated Phase 1 dose escalation/backfill population with advanced EGFR-mutant NSCLC Responses observed in patients with difficult-to-treat C797S/T790M mutations and in patients with brain metastases Phase...
Herbert Loong: Latest Treatment Approaches in EGFR-Positive NSCLC at CUHK Medicine Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, and Steering Committee Member at Lung Cancer Policy Network, shared a post on X:. “Thrilled to have good...
